Team
health

TI-RADS Calculator

The TI-RADS (Thyroid Imaging Reporting and Data System) is a standardized classification developed by the American College of Radiology to stratify thyroid nodules detected on ultrasound. Radiologists, endocrinologists, and sonographers use this 5-category scoring system to quantify malignancy risk and guide clinical management decisions. By evaluating composition, echogenicity, shape, margin characteristics, and focality, practitioners determine whether fine-needle aspiration biopsy is warranted or surveillance monitoring is appropriate.

Last updated:

Creators Adena Benn, BSc
5,315 people find this calculator helpful

Understanding TI-RADS in Thyroid Imaging

TI-RADS provides a structured, reproducible method for risk-stratifying thyroid nodules discovered during ultrasound screening or investigation. Rather than subjective interpretation, the system assigns points based on discrete ultrasound features, producing a cumulative score that maps to five risk categories.

The primary clinical question—whether a nodule warrants biopsy—hinges on this scoring. A benign-appearing nodule (TR1 or TR2) typically requires no intervention. Higher categories trigger escalating management protocols: increased surveillance intervals, fine-needle aspiration biopsy, or referral to thyroid surgery. This standardized approach reduces unnecessary procedures on low-risk lesions while ensuring potentially malignant nodules are investigated.

Fine-needle aspiration biopsy, when performed, uses a thin needle to extract cells from the thyroid under ultrasound guidance. The specimen is then examined cytologically for signs of malignancy, helping confirm the ultrasound-based risk assessment.

TI-RADS Scoring Formula

The final TI-RADS score is calculated by summing individual point values assigned to five ultrasound features. Each feature category contributes 0–3 points based on the imaging appearance, producing a total score ranging from 0 to 17 points.

TI-RADS Score = Composition + Echogenicity + Shape + Margin + Echogenic Foci

  • Composition — Assessment of the nodule's internal makeup: cystic, spongiform, mixed, or solid (0–2 points)
  • Echogenicity — Comparison of nodule brightness to thyroid parenchyma: anechoic, isoechoic/hyperechoic, hypoechoic, or very hypoechoic (0–3 points)
  • Shape — Orientation in the transverse ultrasound plane: wider-than-tall or taller-than-wide (0 or 3 points)
  • Margin — Nodule boundary appearance: smooth/ill-defined, lobulated/irregular, or with extrathyroidal extension (0–3 points)
  • Echogenic Foci — Presence and type of calcifications: none, macrocalcifications, or punctate echogenic foci (0–3 points)

How to Use the TI-RADS Calculator

Input the five ultrasound parameters observed during examination. For each feature, select the descriptor that best matches the nodule's appearance on real-time or stored ultrasound images.

  • Composition: Classify the nodule as entirely cystic/spongiform (0 pts), mixed solid-cystic (1 pt), or solid/nearly solid (2 pts).
  • Echogenicity: Compare internal echogenicity to surrounding thyroid: anechoic (0), iso/hyperechoic (1), hypoechoic (2), or very hypoechoic (3 pts).
  • Shape: Measure in transverse plane—wider than tall scores 0 points; taller than wide scores 3 points.
  • Margin: Smooth or ill-defined margins score 0; lobulated/irregular score 2; extrathyroidal extension scores 3 points.
  • Echogenic Foci: Assess for punctate bright spots (suspicious) versus larger macrocalcifications (benign pattern).

The calculator sums these values and assigns a TI-RADS category (TR1–TR5) with corresponding malignancy risk: TR1 (0.3%), TR2 (1.5%), TR3 (4.8%), TR4 (9.1%), and TR5 (35%). ACR management recommendations then guide follow-up intervals or biopsy timing.

TI-RADS Risk Categories and Clinical Recommendations

TR1 (Benign, 0 points): No follow-up imaging required. Purely cystic nodules without suspicious features fall into this category.

TR2 (Not Suspicious, 1–2 points): No FNA or follow-up needed. These are overwhelmingly benign lesions.

TR3 (Mildly Suspicious, 3 points): Follow-up ultrasound at 12 months; repeat at 24 months if stable. FNA only if clinically indicated.

TR4 (Moderately Suspicious, 4–6 points): FNA recommended. If nondiagnostic, repeat within 3 months. Sonographic follow-up every 6–12 months if benign cytology.

TR5 (Highly Suspicious, ≥7 points): Strongly recommend FNA. Malignancy risk exceeds 35%. Nodules ≥1 cm warrant immediate investigation; those <1 cm may be followed if clinically appropriate, but biopsy is typically pursued.

Nodule size influences management; lesions under 1 cm may be managed conservatively even if intermediate risk, whereas larger nodules trigger more aggressive protocols.

Key Considerations When Applying TI-RADS

Accurate TI-RADS scoring depends on proper ultrasound technique and feature recognition. Keep these pitfalls in mind:

  1. Indeterminate Features Require Conservative Defaults — When nodule composition, echogenicity, or margins are unclear—such as in heavily calcified nodules or poor acoustic windows—default to the more suspicious category. Classify unclear composition as solid and uncertain echogenicity as isoechoic, applying ill-defined margins if uncertain. This conservative approach prevents underestimation of risk.
  2. Shape Assessment Must Use Transverse Plane — Taller-than-wide assessment applies only to the transverse (short-axis) plane. Measuring in the sagittal plane or using incorrect orientation can misclassify a nodule's shape and inflate or deflate the score. Always perform assessment with the nodule's widest diameter in view.
  3. Punctate Foci Are More Suspicious Than Macrocalcifications — Large coarse calcifications (macrocalcifications) often indicate benign adenomatous or colloid nodules. Small punctate echogenic foci, particularly if distributed throughout the nodule, carry higher suspicion for malignancy and score more heavily. Distinguishing these patterns is critical for accurate risk stratification.
  4. TI-RADS Does Not Replace Clinical Judgment — The system standardizes ultrasound feature assessment but does not account for patient age, gender, family history, prior radiation exposure, or symptoms. A TR2 nodule in a patient with prior head/neck radiation may warrant closer surveillance. Always integrate TI-RADS results with clinical context and patient-specific risk factors.

Frequently Asked Questions

What does TI-RADS stand for and who developed it?

TI-RADS is the Thyroid Imaging Reporting and Data System, established by the American College of Radiology (ACR) in 2015. It was created to standardize the ultrasound assessment of thyroid nodules, replacing subjective terminology with a systematic scoring approach. The system incorporates five key ultrasound features to calculate a cumulative score, enabling radiologists and clinicians to communicate nodule risk consistently and guide evidence-based management decisions across different healthcare settings.

What is the difference between a TR3 and TR4 nodule?

TR3 nodules score 3 points and carry a 4.8% malignancy risk, typically warranting surveillance ultrasound at 12 months rather than immediate biopsy. TR4 nodules score 4–6 points with a 9.1% malignancy risk and generally require fine-needle aspiration biopsy to obtain cytology. The management threshold differs: TR3 is managed conservatively with imaging follow-up, whereas TR4 calls for tissue diagnosis. This distinction helps prevent unnecessary biopsies on low-risk lesions while ensuring intermediate-risk nodules receive appropriate investigation.

How often should I monitor a benign TI-RADS nodule?

Benign nodules classified as TR1 (0 points) require no follow-up imaging. TR2 nodules (1–2 points) similarly need no surveillance. For TR3 lesions, ultrasound follow-up is recommended at 12 months, then at 24 months if unchanged. Nodule size also influences follow-up: those under 1 cm may be monitored less frequently (every 3–5 years), while nodules larger than 1 cm warrant closer surveillance (every 1–2 years) even if lower-risk, due to cumulative malignancy risk with growth.

Can TI-RADS accurately distinguish benign from malignant thyroid nodules?

TI-RADS is a risk-stratification tool, not a diagnostic test that definitively proves malignancy or benignity. TR1–TR2 nodules have low malignancy risk (0.3–1.5%) and often need no further investigation. However, overlap exists: some TR5 nodules (high-risk) prove benign on biopsy, while rarely, a TR2 nodule may harbor occult cancer. TI-RADS assigns probability, guides resource allocation, and reduces unnecessary biopsies, but final diagnosis requires cytologic or histologic confirmation via fine-needle aspiration and Bethesda classification.

What happens if my TI-RADS score is borderline between two categories?

TI-RADS scoring produces discrete point totals; a nodule with 3 points is clearly TR3, not borderline TR2/TR3. However, if clinical uncertainty exists—such as difficulty assessing a feature—apply conservative scoring defaults. Uncertain features should be scored toward the higher-risk category to avoid missing malignancy. Discussion with the radiologist and integration of clinical context (nodule size, growth rate, patient symptoms) can clarify the appropriate management pathway even when scores are intermediate.

Does nodule size affect TI-RADS scoring or management?

Size is not a direct component of the TI-RADS score itself, which relies on ultrasound feature assessment. However, size strongly influences clinical management: nodules under 1 cm may be followed conservatively even if TR3–TR4, whereas nodules over 1 cm with the same score typically warrant prompt biopsy. Additionally, larger nodules have higher cumulative malignancy risk and may cause compressive symptoms, justifying more aggressive investigation. Always consider both the TI-RADS category and absolute nodule diameter when planning follow-up.

More health calculators (see all)

Caffeine Calculator Social Distancing Calculator Testosterone to Estradiol Ratio Calculator Plasma Osmolality Calculator Carbohydrates Calculator Geriatric BMI Calculator Levothyroxine Dosage Calculator Fatigue Severity Scale Calculator